Table 6.
Transplant-related Morbidity
| Tacrolimus at Initial Steady State | |||
|---|---|---|---|
| <10 ng/mL (N=176) | ≥10 ng/mL (N=34) | Total (N=210) | |
| Continue Tacrolimus on day +30, n (%) | |||
| No | 13 (7.4%) | 4 (11.8%) | 17 (8.1%) |
| Yes | 163 (92.6%) | 30 (88.2%) | 193 (91.9%) |
| Reason for Tacrolimus discontinuation, n/total n who discontinued TAC | |||
| Renal insufficiency | 4/13 | 2/4 | 6/17 |
| Neurotoxicity/PRES | 7/13 | 0 | 7/17 |
| Engraftment failure | 0 | 2/4 | 2/17 |
| Death | 1/13 | 1/4 | 2/17 |
| Hemodialysis within day +100, n (%) | |||
| No | 171 (97.2%) | 31 (91.2%) | 202 (96.2%) |
| Yes | 5 (2.8%) | 3 (8.8%) | 8 (3.8%) |
| ICU Stay, n (%) | |||
| No | 161 (91.5%) | 29 (85.3%) | 190 (90.5%) |
| Yes | 15 (8.5%) | 5 (14.7%) | 20 (9.5%) |
| Sinusoidal obstruction syndrome, n (%) | |||
| No | 173 (98.3%) | 33 (97.1%) | 206 (98.1%) |
| Yes | 3 (1.7%) | 1 (2.9%) | 4 (1.9%) |
| Hemorrhagic Cystitis Grade, n (%) | |||
| No | 123 (69.9%) | 28 (82.4%) | 151 (71.9%) |
| Yes | 53 (30.1%) | 6 (17.6%) | 59 (28.1%) |